Interaction Toxicity Study between P-glycoprotein Inhibitor (Captopril) and Inducer (Spironolactone) with Their Substrate (Lovastatin) in Male Rats
Article Sidebar
Main Article Content
Abstract
An interaction toxicity study was performed to evaluate and compare the effect of P-glycoprotein (P-gp) inhibitor (captopril) and inducer (spironolactone) on their common substrate (lovastatin) that were done by comparing LD50 of the acute study with their chronic form then with those combined therapeutic doses administered for 90 days. Therefore, isobolographic analysis and chronicity index were used as the parameters for this study. Forty rats were allocated into five groups according to the used treatment into: captopril, spironolactone, lovastatin, captopril + lovastatin and spironolactone + lovastatin using up and down method to determine their acute exposure LD50 while ninety rats were used to perform the chronic stage of the study divided equally into six groups according to daily dosing regimen as following G1- control group administered distilled water orally; G2 administered captopril 0.7 mg/kg BW orally; G3-administered spironolactone 1.4 mg/kg BW orally; G4- administered lovastatin 0.57 mg/kg BW orally; G5-administered spironolactone1.4 mg/kg BW orally and lovastatin 0.57 mg/kg BW, G6- administered captopril 0.7 mg/kg BW and lovastatin 0.57 mg/kg BW orally. The results of isobolographic analysis showed that the sort of interaction between P-gp inhibitor (captopril) and lovastatin alone and as combined administration showed to be antagonistic after acute administration while it was synergistic after chronic administration; for P-gp inducer, spironolactone and lovastatin were additive after acute administration and antagonistic after chronic administration. Chronicity index results showed that both captopril and lovastatin accumulated after administered each alone and showed more accumulation after their combined administration while the chronicity index for P-gp inducer (spironolactone) and lovastatin showed less total concentration in the body burden after their combined administration than alone one. In conclusion, it seems that P-gp inhibitor (captopril) causes accumulation of itself and substrate (lovastatin), while P-gp inducer (spironolactone) causes reduction on the body burden of itself as well as lovastatin possibly due to their effects on the kinetics of the body and this may affect the efficacy and safety of drugs.
Correspondence: [email protected]
Received: 12 March 2020
Accepted: 21 June 2020
Published: 28 December 2020
Downloads
Article Details
How to Cite
References
Gameiro M, Silva R, Rocha-Pereira C, Carmo H, Carvalho F, Bastos MD. Cellular models and in vitro assays for the screening of modulators of P-gp, MRP1 and BCRP. Mol. J. 2017;22(4): 600.
Litman T, Druley T, Stein W, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. CMLS, Cell. Mol. Life Sci. 2001;58(7):931-959.
Silva R, Vilas-Boas V, Carmo H, Dinis-Oliveira RJ, Carvalho F, de Lourdes. Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy. Pharmacol. Ther. 2015; 149:1-23.
Finch A, Pillans P. P-glycoprotein and its role in drug-drug interactions. Aust Prescr. 2014; 37(4): 137-139.
MarchettiS, Schellens HM. Clinical Relevance: Drug.Drug Interactions, Pharmacokinetics, Pharmacodynamics, and Toxicity. In:You G, Morris ME, editors. Drug Transporters: Molecular Characterization and Role in Drug Disposition. 2nd ed. New Jersey: John Wiley & Sons, Inc.; 2014. p. 433-471.
Padowski JM, Pollack GM. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Methods Mol. Biol. 2010; 596: 359]384.
Miguel-Carrasco JL, Zambrano S, Blanca AJ, Mate A, Vazquez CM. Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB. J. inflamm. 2010;7(1):21.
Gan Z, Huang D, Jiang J, Li Y, Li H, Ke Y. Captopril alleviates hypertension-induced renal damage, inflammation, and NF-ƒÈB activation. Braz. J. Med. Biol. Res. 2018;51(11).
Lindle KA, Dinh K, Moffett BS, Kyle WB, Montgomery NM, Denfield SD, et al. Angiotensin-converting enzyme inhibitor nephrotoxicity in neonates with cardiac disease. PediatrCardiol. 2014;35(3):499-506.
Antunes AM, Guerrante RD, Avila JD, Lins Mendes FM, Fierro IM. Case study of patents related to captopril, Squibbfs first blockbuster. Expert Opin. Ther. Pat. 2016; 26(12): 1449-57.
Hess CN, Low Wang CC, Hiatt WR. PCSK9 inhibitors: mechanisms of action, metabolic effects, and clinical outcomes. Annu.Rev. Med. 2018;69: 133-45.
Bitzur R, Cohen H, Kamari Y, Harats D. Intolerance to statins: mechanisms and management. Diab.Care. 2013; 36(2): S325-30.
Batterink J, Stabler SN, Tejani AM, Fowkes CT. Spironolactone for 14. hypertension. Cochrane Database Syst. Rev. 2010;(8): 1-36.
Williams EM, Katholi RE, Karambelas MR. Use and side]effect profile of spironolactone in a private cardiologist's practice. Clinic. Cardio. 2006; 29 (4): 149-53.
Dixon WJ. The up-and-down method for small samples. J. Americ. Statis. Assoc. 1965; 60(312): 967-78.
Mustafa KA, Al-Baggou BK. Toxicological and neurobehavioral effects of chlorpyrifos and deltamethrin insecticides in mice. Iraqi.J.Vet.sci.2020; 34(1): 189-96.
Tallarida RJ. Drug combinations: tests and analysis with isoboles. Curr.Proto. Pharmacol. 2016; 72(1): 9-19.
Klaassen CD. Casarett and Doullfs Toxicology. The Basic Science of Poisons. 7th edition. United State of America: Macmillan Publishing Company New York; 2008 p. 26.
Fardel O, Kolasa E, Le Vee M. Environmental chemicals as substrates, inhibitors or inducers of drug transporters: implication for toxicokinetics, toxicity and pharmacokinetics. Expert Opin. Drug metab Toxicol. 2012 ;8(1): 29-46.
Lin JH. Drug.drug interaction mediated by inhibition and induction of P-glycoprotein. Adv. Drug Deliv. Rev. 2003;55(1): 53-81.
Fromm MF. Importance of P-glycoprotein at blood.tissue barriers. Trends Pharmacol.Sci. 2004;25(8): 423-9.
Balayssac D, Authier N, Cayre A, Coudore F. Does inhibition of P-glycoprotein lead to drug.drug interactions? Toxicol.Lett. 2005;156(3):319-29.
Glaeser H. Importance of P-glycoprotein for drug.drug interactions. Handb. Exp. Pharmacol. 2011;(201): 285-297.
Lund M, Petersen TS, Dalhoff KP. Clinical implications of P-glycoprotein modulation in drug.drug interactions. Drugs. 2017;77(8): 859-83.
Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobio. 2008;38(7-8): 802-32.